Obsidian Therapeutics (NASDAQ:OBX) Stock Has Consensus Target Price of $39.00

Obsidian Therapeutics (NASDAQ:OBX) has earned a consensus recommendation of “Moderate Buy” from the seven research firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $39.00.

A number of analysts recently commented on OBX shares. Weiss Ratings began coverage on Obsidian Therapeutics in a research report on Wednesday, September 2nd. They issued a “sell (d-)” rating for the company. Piper Sandler initiated coverage on Obsidian Therapeutics in a report on Wednesday, August 5th. They issued an “overweight” rating and a $42.00 price target on the stock. Zacks Research raised Obsidian Therapeutics to a “hold” rating in a research note on Thursday, August 6th. Lifesci Capital started coverage on Obsidian Therapeutics in a report on Tuesday, August 18th. They set an “outperform” rating and a $43.00 price objective for the company. Finally, TD Cowen began coverage on Obsidian Therapeutics in a research report on Thursday, August 6th. They set a “buy” rating on the stock.

Obsidian Therapeutics Trading Down 16.9%

OBX stock opened at $10.99 on Thursday. The stock’s 50-day moving average is $14.91. Obsidian Therapeutics has a 1 year low of $10.60 and a 1 year high of $49.97.

About Obsidian Therapeutics

Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered TIL cell therapies for the treatment of patients with solid tumors. Obsidian Therapeutics Inc is based in CAMBRIDGE, Mass.